<p>According to a report from the Economic Information Daily on the 6th, foreign media cited informed sources revealing that Chinese biotechnology company Agna Biopharmaceuticals Co., Ltd. has selected banks for its initial public offering (IPO) in Hong Kong, with a financing scale potentially reaching hundreds of millions of dollars. Informed sources indicated that this company, supported by Golden Apricot Capital, is collaborating with Bank of America, CICC, Jefferies Financial Group Inc., and JPMorgan Chase. The company has secretly submitted its IPO application, but details such as scale and timing are still under discussion. Agna Biopharmaceuticals, Golden Apricot Capital, and CICC have not responded to requests for comment. Representatives from Bank of America, Jefferies Financial Group Inc., and JPMorgan declined to comment. According to its website, Agna Biopharmaceuticals was established in 2021 and is dedicated to developing siRNA therapies for various diseases, including cardiovascular diseases, rare diseases, metabolic diseases, and viral infections. (bi)</p>

601995

03908

<p>Agna Biopharmaceuticals Co., Ltd. has chosen to conduct its initial public offering (IPO) in Hong Kong, with a financing scale of up to several hundred million dollars. The company has confidentially submitted its IPO application in collaboration with Bank of America, CICC, Jefferies Financial Group Inc., and JPMorgan Chase, with specific scale and timing still under discussion. Agna Biopharmaceuticals was established in 2021 and focuses on developing siRNA therapies for the treatment of various diseases</p>

- Chinese biotech company Agna Biopharmaceuticals has selected banks for its initial public offering (IPO) in Hong Kong, aiming to raise several hundred million dollars.  
- The company, backed by Golden Pine Capital, is collaborating with Bank of America, CICC, Jefferies Financial Group, and JPMorgan, having submitted a confidential IPO application with details still under discussion.  
- Founded in 2021, Agna focuses on developing siRNA therapies for various diseases, including cardiovascular conditions, rare diseases, metabolic disorders, and viral infections.

etnet

[New Stock Listing] Agna Biopharmaceuticals reportedly has selected Hong Kong IPO banks to raise hundreds of millions of dollars